ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
The early diagnostic value of lung cancer autoantibodies and tumor markers in lung cancer.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the diagnostic value of seven lung cancer-related autoantibodies (7-AABs) and four tumor markers (4-TMs) for the early detection of lung cancer, aiming to assess their combined effectiveness compared to individual applications.
methodsWe analyzed serum samples from 110 lung cancer patients and 50 age-matched patients with benign lung nodules. Serum concentrations of 7-AABs (including SOX2, GAGE 7, CAGE, MAGE A1, P53, GBU4-5, and PGP9.5) and 4-TMs (CEA, NSE, CYFRA21‑1, and SCCA) were measured using ELISA. Receiver operating characteristic (ROC) curves were conducted to evaluate the value of combining tumor markers with serum 7-AABs for early diagnosis of lung cancer.
resultsIn the malignant group, significantly elevated levels of seven autoantibodies (7-AABs), including SOX2, GAGE 7, CAGE, MAGE A1, P53, GBU4-5, and PGP9.5, as well as four tumor markers (4-TMs), namely CEA, NSE, CYFRA21‑1, and SCCA, were observed compared to the benign group, with markedly higher positivity rates for these biomarkers in the malignant group. The combined analysis of 7-AABs and 4-TMs yielded the highest diagnostic accuracy with an AUC of 0.977, significantly improving sensitivity and specificity. Notably, SOX2 and CEA showed distinct patterns across different lung cancer histological types, enhancing diagnostic differentiation. Furthermore, decision curve analysis (DCA) demonstrated the superior clinical net benefit of the 7-AABs full model over a baseline P53 model across a wide range of risk thresholds, providing a more clinically relevant metric for evaluating diagnostic performance.
conclusionOur findings suggest that combining autoantibodies and tumor markers may improve the early detection of lung cancer, offering a potentially non-invasive, cost-effective, and accurate diagnostic tool. However, due to the limitations of our study, such as the relatively small sample size and single-center design, these results need to be validated in larger, multi-center cohorts. This combined biomarker approach could complement existing screening methods, but further research is required to confirm its clinical utility and integration into current screening practices.
Indexed as
Identifiers
41824177What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.